In vivo properties of oncostatin M.
Wallace
P M
PM
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
Macmaster
J F
JF
Rillema
J R
JR
Rouleau
K A
KA
Hanson
M B
MB
Burstein
S A
SA
Shoyab
M
M
D000209:Acute-Phase Proteins / Q000096:biosynthesis; D000818:Animals; D016207:Cytokines / Q000493:pharmacokinetics / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects; D015850:Interleukin-6 / Q000096:biosynthesis / Q000494:pharmacology; D008657:Metabolic Clearance Rate; D051379:Mice; D053683:Oncostatin M; D010455:Peptides / Q000493:pharmacokinetics / Q000494:pharmacology*; D010976:Platelet Count; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein / Q000096:biosynthesis; D013921:Thrombocytopenia / Q000188:drug therapy; D014018:Tissue Distribution
D000209:Acute-Phase Proteins; D016207:Cytokines; D015850:Interleukin-6; C508352:Osm protein, mouse; D010455:Peptides; D011994:Recombinant Proteins; D000685:Serum Amyloid A Protein; D053683:Oncostatin M